Overview

Location [1]
10q11.21
Pathways
Receptor tyrosine kinase/growth factor signaling, Kinase fusions
Protein [2]
Extracellular cell-membrane anchored RET cadherin 120 kDa fragment
Synonyms [1]
RET-ELE1, PTC, CDHR16, CDHF12, MEN2B, MEN2A, MTC1, HSCR1

The RET gene (ret proto-oncogene), encodes the proto-oncogene tyrosine-protein kinase receptor Ret, a receptor tyrosine kinase (RTK). Activating point mutations in RET can give rise to the hereditary cancer syndrome, multiple endocrine neoplasia 2 (MEN2; PMID: 11061555). Activating somatic point mutations in RET are associated with sporadic medullary thyroid cancer (PMID: 16946010; PMID: 11061555). Oncogenic kinase fusions involving the RET gene are found in non-small cell lung cancers (PMID: 22395697).

 

RET is altered in 2.21% of all cancers with lung adenocarcinoma, colon adenocarcinoma, thyroid gland medullary carcinoma, cutaneous melanoma, and melanoma having the greatest prevalence of alterations [3].

RET GENIE Cases - Top Diseases

The most common alterations in RET are RET Mutation (2.78%), RET Loss (0.18%), RET M918T (0.13%), RET Amplification (0.08%), and RET D567N (0.03%) [3].

RET GENIE Cases - Top Alterations

Biomarker-Directed Therapies

Significance of RET in Diseases

Non-Small Cell Lung Carcinoma +

Thyroid Gland Medullary Carcinoma +

Thyroid Gland Carcinoma +

Malignant Solid Tumor +

Melanoma +

Squamous Cell Lung Carcinoma +

Colorectal Carcinoma +

Renal Cell Carcinoma +

Pancreatic Carcinoma +

Breast Carcinoma +

Non-Squamous Non-Small Cell Lung Carcinoma +

Endometrial Carcinoma +

Urothelial Carcinoma +

Lung Carcinoma +

Bladder Carcinoma +

Esophageal Carcinoma +

Ovarian Carcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Head And Neck Carcinoma +

Hepatocellular Carcinoma +

Multiple Myeloma +

Acute Lymphoblastic Leukemia +

Gastric Adenocarcinoma +

Gastric Carcinoma +

Oropharyngeal Carcinoma +

Lymphoma +

Lung Adenocarcinoma +

Cancer +

Malignant Uterine Neoplasm +

Leukemia +

Non-Hodgkin Lymphoma +

Bile Duct Carcinoma +

Malignant Central Nervous System Neoplasm +

B-Cell Non-Hodgkin Lymphoma +

Acute Myeloid Leukemia +

Hepatobiliary Neoplasm +

Malignant Hepatobiliary Neoplasm +

High Grade Ovarian Serous Adenocarcinoma +

Thyroid Gland Papillary Carcinoma +

Pancreatic Adenocarcinoma +

Prostate Carcinoma +

Malignant Salivary Gland Neoplasm +

Soft Tissue Sarcoma +

Adrenal Cortex Carcinoma +

Adrenal Gland Pheochromocytoma +

Alveolar Soft Part Sarcoma +

Bronchogenic Carcinoma +

Cervical Carcinoma +

Cervical Squamous Cell Carcinoma +

Chronic Myeloid Leukemia +

Clear Cell Sarcoma Of Soft Tissue +

Esophageal Squamous Cell Carcinoma +

Ewing Sarcoma +

Gallbladder Carcinoma +

Gastrointestinal Stromal Tumor +

Head And Neck Squamous Cell Carcinoma +

Hepatoblastoma +

Lip And Oral Cavity Carcinoma +

Malignant Laryngeal Neoplasm +

Mesothelioma +

Nasal Cavity And Paranasal Sinus Carcinoma +

Nasopharyngeal Carcinoma +

Osteosarcoma +

Poorly Differentiated Thyroid Gland Carcinoma +

Rhabdomyosarcoma +

Wilms Tumor +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.